Literature DB >> 23010743

DNA methylation of NDRG2 in gastric cancer and its clinical significance.

Xiaojing Chang1, Zhenhua Li, Jinguo Ma, Peng Deng, Shuanglong Zhang, Yu Zhi, Jing Chen, Dongqiu Dai.   

Abstract

BACKGROUND: Gastric cancer is one of the most common digestive malignancies worldwide. N-myc downstream-regulated gene 2 (NDRG2) is a differentiation-related gene that is considered to be a metastasis suppressor gene. In this study, we examined the expression and DNA methylation of NDRG2 in gastric cancer cell lines and tissues, as well as its clinical significance.
METHODS: Six gastric cancer cell lines and 42 paired normal and gastric cancer tissue samples were used to assess NDRG2 mRNA expression using RT-PCR. NDRG2 DNA methylation status was evaluated by methylation-specific PCR (MSP) in gastric cancer cell lines and tissues. The suppression of NDRG2 in BGC823 cells by siRNA transfection was utilized to detect the role of NDRG2 in gastric cancer progression.
RESULTS: NDRG2 mRNA was down-regulated in gastric cancer cell lines and tissues, and its expression was just related to lymph node metastasis (p = 0.032). MSP showed methylation of NDRG2 in 54.0 % (47/87) of primary gastric cancer specimens and in 20.0 % (16/80) of corresponding nonmalignant gastric tissues. NDRG2 methylation was related to depth of tumor invasion, Borrmann classification and TNM stage (p < 0.05). Upon treatment with 5-aza-2'-deoxycytidine and trichostatin A, NDRG2 expression was upregulated in HGC27 cells, and demethylation of the highly metastatic cell line, MKN45, inhibited cell invasion. Furthermore, the suppression of NDRG2 by siRNA transfection enhanced BGC823 cells invasion.
CONCLUSIONS: Our results suggest that the aberrant methylation of NDRG2 may be mainly responsible for its downregulation in gastric cancer, and may play an important role in the metastasis of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010743     DOI: 10.1007/s10620-012-2393-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB.

Authors:  Wen-Jing Shen; Dong-Qiu Dai; Yue Teng; Hong-Bo Liu
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

2.  Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.

Authors:  Satoshi Yamashita; Yoshimi Tsujino; Kazuki Moriguchi; Masae Tatematsu; Toshikazu Ushijima
Journal:  Cancer Sci       Date:  2006-01       Impact factor: 6.716

3.  DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.

Authors:  Maria Chimonidou; Areti Strati; Alexandra Tzitzira; Georgia Sotiropoulou; Nikos Malamos; Vasilis Georgoulias; Evi S Lianidou
Journal:  Clin Chem       Date:  2011-06-23       Impact factor: 8.327

4.  Expression and prognostic value of NDRG2 in human astrocytomas.

Authors:  Li Li; Jiang Wang; Xuefeng Shen; Ling Wang; Xiaoning Li; Yonghong Liu; Ming Shi; Gang Zhao; Yanchun Deng
Journal:  J Neurol Sci       Date:  2011-06-25       Impact factor: 3.181

5.  NDRG2 expression and mutation in human liver and pancreatic cancers.

Authors:  Xiao-Lan Hu; Xin-Ping Liu; Shu-Xin Lin; Yan-Chun Deng; Na Liu; Xia Li; Li-Bo Yao
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

6.  NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells.

Authors:  Jin Zheng; Qiang Liu; Yan Li; Jiandong Yang; Ji Ma; Fang Yu; Hengjun Shi; Qinyou Ren; Rui Zhang; Jin Zhang; Yan Xue; Yurong Tao; Ning Jiang; Hang Guo; LiBo Yao; Wenchao Liu
Journal:  Asian Pac J Cancer Prev       Date:  2010

7.  Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines.

Authors:  Na Liu; Lifeng Wang; Xinping Liu; Qi Yang; Jing Zhang; Wei Zhang; Yousheng Wu; Lan Shen; Yingqi Zhang; Angang Yang; Hua Han; Jian Zhang; Libo Yao
Journal:  Biochem Biophys Res Commun       Date:  2007-04-20       Impact factor: 3.575

8.  Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes.

Authors:  Anna Mordalska; Joanna Latek; Tomasz Ferenc; Lech Pomorski; Elzbieta Gałecka; Arkadiusz Zygmunt; Andrzej Lewiński
Journal:  Thyroid Res       Date:  2010-08-30

9.  Profile of aberrant CpG island methylation along multistep gastric carcinogenesis.

Authors:  Gyeong Hoon Kang; Sun Lee; Jung-Sun Kim; Hwoon-Yong Jung
Journal:  Lab Invest       Date:  2003-04       Impact factor: 5.662

10.  Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.

Authors:  Anders Lorentzen; Lotte K Vogel; Rikke H Lewinsky; Mona Saebø; Camilla F Skjelbred; Sine Godiksen; Geir Hoff; Kjell M Tveit; Inger Marie Bowitz Lothe; Tone Ikdahl; Elin H Kure; Cathy Mitchelmore
Journal:  BMC Cancer       Date:  2007-10-12       Impact factor: 4.430

View more
  17 in total

1.  Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.

Authors:  Mohit Sachdeva; Rebecca D Dodd; Zhiqing Huang; Carole Grenier; Yan Ma; Dina C Lev; Diana M Cardona; Susan K Murphy; David G Kirsch
Journal:  Cancer Lett       Date:  2015-08-24       Impact factor: 8.679

2.  The FENDRR/miR-214-3P/TET2 axis affects cell malignant activity via RASSF1A methylation in gastric cancer.

Authors:  Zhaocai He; Xin Wang; Changhao Huang; Yu Gao; Chen Yang; Pengwei Zeng; Zihua Chen
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

Review 3.  Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.

Authors:  Jun Nakamura; Tomokazu Tanaka; Yoshihiko Kitajima; Hirokazu Noshiro; Kohji Miyazaki
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 4.  Pathogenetic mechanisms in gastric cancer.

Authors:  Jing Shi; Yi-Ping Qu; Peng Hou
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 5.  Epigenetics: an emerging player in gastric cancer.

Authors:  Changwon Kang; Ji-Joon Song; Jaeok Lee; Mi Young Kim
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

6.  Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.

Authors:  Shingo Nakahata; Tomonaga Ichikawa; Phudit Maneesaay; Yusuke Saito; Kentaro Nagai; Tomohiro Tamura; Nawin Manachai; Norio Yamakawa; Makoto Hamasaki; Issay Kitabayashi; Yasuhito Arai; Yae Kanai; Tomohiko Taki; Takaya Abe; Hiroshi Kiyonari; Kazuya Shimoda; Koichi Ohshima; Akira Horii; Hiroshi Shima; Masafumi Taniwaki; Ryoji Yamaguchi; Kazuhiro Morishita
Journal:  Nat Commun       Date:  2014-02-26       Impact factor: 14.919

7.  Glioma Malignancy-Dependent NDRG2 Gene Methylation and Downregulation Correlates with Poor Patient Outcome.

Authors:  Daina Skiriutė; Giedrius Steponaitis; Paulina Vaitkienė; Mykolas Mikučiūnas; Kęstutis Skauminas; Arimantas Tamašauskas; Arunas Kazlauskas
Journal:  J Cancer       Date:  2014-05-13       Impact factor: 4.207

8.  Clinical significance of epigenetic silencing and re-expression of O6-methylguanine-DNA methyltransferase using epigenetic agents in laryngeal carcinoma.

Authors:  Jing Yang; Xin-Bing Zhu; Li-Xia He; Zhao-Wei Gu; Ming-Zhu Jin; Wen-Yue Ji
Journal:  Oncol Lett       Date:  2014-11-03       Impact factor: 2.967

9.  Ndrg2 promoter hypermethylation triggered by helicobacter pylori infection correlates with poor patients survival in human gastric carcinoma.

Authors:  Zhi-Qiang Ling; Ming-Hua Ge; Xiao-Xiao Lu; Jin Han; Yi-Chen Wu; Xiang Liu; Xin Zhu; Lian-Lian Hong
Journal:  Oncotarget       Date:  2015-04-10

Review 10.  Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer.

Authors:  Wei Hu; Chongxi Fan; Peng Jiang; Zhiqiang Ma; Xiaolong Yan; Shouyin Di; Shuai Jiang; Tian Li; Yedong Cheng; Yang Yang
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.